

Novel Process For Synthesis of 2,3-dihydro-1,3,4-Thiadiazole Derivative

Nadhir Najim Al-Gatrinie
Department of Chemistry,
Faculty of Science, Babylon
University

Fadhel Omran Essa
Department of General
Science, Faculty of Basic
Education, Babylon
University

Abidallah.M.Ali
Department of chemistry,
Faculty of science for
women education, Kufa
University


(NJC)

(Received on 7/5 /2007)


(Accepted for publication on 9/12 /2007)

Abstract


In this study a series of compounds (**3,4,5a,5b,5c,5d**) with 2,3-dihydro-1,3,4-thiadiazole were synthesized from p-hydroxy benzaldehyde. The mechanism of this studied was discussed. The chemical of the compounds were elucidated by their IR and ¹H-NMR spectral date.



(3)



(4)



(5)

R =

a= CH₃.....

b= C₂H₅.....

c= C₃H₇.....

d= Ph-CH₂.....

keywords : 2,3-Dihydro-1,3,4-Thiadiazole, Novel, Benzaldehyde.

الخلاصة

(3,4,5a,5b,5c,5d)

-4 3 1-

-3 2

Introduction:

1,3,4- Thiadiazoles attracted the great attention after the discovery of sulfa drugs and their potent representative bearing this heterocyclic ring . Several 1,3,4- Thiadiazoles have been found biologically active, e.g. they showed the anti-Cancer and antiviral activity⁽¹⁻⁹⁾ anti-inflammatory⁽⁶⁾ anticonvulsant⁽⁸⁾ H-2 antagonist⁽⁷⁾ antibacterial⁽⁵⁾.

Likewise a 1,3,4-thiadiazole nucleus which incorporates an N-C-S linkage exhibits a large number of biological activities⁽¹⁰⁾.

As apart of our program amid to developing for synthesis of new compounds containing 1,3,4- Thiadiazoles heterocyclic rings, we reported here the facile and novel rout to synthesis of 2,3 – dihydro- 1,3,4-Thiadiazole heterocyclic ring and their derivatives through the intermolecular cyclization as shown in this

novel synthesis that was illustrated in Scheme 1 and Scheme 2.

Experimental:**1-General:**

The solvents used were purified by standard procedures. The melting point (m.p) was determined on an electrothermal digital melting point apparatus and uncorrected. The (¹H-NMR) spectra were recorded on 400MHz (JEOL, JNM-ECP400, FT-NMR system), (300MHz with AC300 instrument from Bruker company) spectrometer in CDCl₃. The spectral data is reported in delta (δ) units relative to TMS reference peak. Infrared (IR) spectra were recorded by using SHIMADZU FT-IR spectrometer(v in cm⁻¹).

2. Procedure:

A. General procedure for synthesis compound (3)

(4-Hydrazonomethyl-phenol)

In stirred (30ml) of absolute ethanol added (lg, 0.008 mole) of p-hydroxy benzaldehyde(1) with (0.4lg, 0.008 mole) of hydrazine hydrate (2). After the addition was complete, the reaction mixture was refluxed for 24hr then cooled. The solid

that precipitate was filtered off, recrystallized by ethanol all data for this compound in table -1-

B. General procedure for synthesis compound (4).

(2-(4-Methoxy-phenyl)-5-methylsulfonyl-2,3-dihydro-[1,3,4]thiadiazole)

Compound (3) (lg, 0.0073 mole) were dissolved in absolute ethanol (30ml). Then the solution was added to the solution of (0.577 mole) of CS₂ with continuous stirring at 60 C⁰. The reaction was then refluxed and monitored by TLC. After consumption of the starting material, added anhydrous sodium carbonate (0.78

mole) and (15ml) of cold distilled water, after 2hr of stirring added drop wise (3ml) of HCl (30%). The mixture was cooled to room temperature and separated the organic layer drying by MgSO₄. The mixture was cooled to room temperature to form yellow precipitate, The crude solid was then filtered and recrystallized from

ethanol to yield the compound (4). All data in table -1-

C. General procedure for synthesis compound (5).

Compound (4) (0.5g, 0.0023) were dissolved in 20ml of absolute ethanol. Then the solution was added to (0.234g, 0.0046 mole-0.25g, 0.0046 mole-0.37g, 0.0046 mole-0.596g, 0.0046 mole) for


(CH₃Cl, C₂H₅Cl, n-C₃H₇Cl and Ph-CH₂Cl) alkyl halide respectively continuous stirring at (r.t) in basic media. The reaction was then refluxed. The mixture was cooled to (r.t) we see yellow precipitate in the bottom of the (r.b.flask). The crude solid was then filtered and recrystallized from ethanol all data for derivatives in table -1- and their names are:

(5a): 2-(4-Methoxy-phenyl)-5-methylsulfanyl-2,3-dihydro-[1,3,4]thiadiazole

(5b): 2-(4-Ethoxy-phenyl)-5-ethylsulfanyl-2,3-dihydro-[1,3,4]thiadiazole

(5c): 2-(4-Propoxy-phenyl)-5-propylsulfanyl-2,3-dihydro-[1,3,4]thiadiazole

(5d): 2-(4-Benzyloxy-phenyl)-5-benzylsulfanyl-2,3-dihydro-[1,3,4]thiadiazole



Scheme (1): Explain the route of synthesis compound (3,4 and 5)

Results and discussion:

The synthesis of the target derivatives (**4**) began by condensing carbon disulfide with 4- Hydrazonomethyl-phenol under basic condition (Scheme1). The compound (**4**) was obtained in 61% yield, the IR and ¹NMR spectra was illustrated in fig 2 and 4 respectively.


The mechanism of this reaction illustrated as shown in (Scheme 2).The (table1) reports the results of complete ¹H-NMR & IR spectra and it is important to point out , these spectral data was confirmed the structure of these compounds.

The presence of chemical shift (δ) at (4.93-4.95) δ and (7.7-7.9) δ indicated the appear of dihydro in heterocyclic 1,3,4-Thiadiazole ring in all derivatives **5a,5b, 5c** and **5d**, fig-3- as example for compound (**5c**).

The purity of the isolated compounds was checked by TLC in different solvents.

The characterization of the synthesized compound (**3**) is based on the infrared & ¹H-NMR data (Table 1), the IR spectra in fig-1- confirmed this compound.

The infrared spectra of compound (**3**) showed characteristic OH /NH₂ absorption in the region 3300-3100 cm⁻¹, which was eliminated by the formation of dihydro-1,3,4-Thiadiazole (**4**) heterocyclic ring and showed absorption peak in 2570-2630 cm⁻¹ attributed to SH. The absence of NH and presence of S-H absorptions established that all the isolated 1,3,4-thiadiazole are in their thiole rather than in the hydrazine form as in fig illustrated below. In the ¹H-NMR spectra of these compounds the protons were observed in the expected region as shown in (Table 1).



Scheme 2 The mechanism for synthesis of compounds (3,4 and 5)

# of compounds	Structure	Yield % color	IR ν max (Cm ⁻¹)	¹ H-NMR (δ)	m.p (C ^o)
3		75% Yellow	3300, 3100	2.0 (s, 2H, NH ₂), 5.1 (s, 1H, OH), 6.8 (d, 2H, Ar), 7.4 (d, 2H, Ar), 8.1 (s, 1H, CH=N)	270-271
4		61% yellow	749, 1243, 1620, 3310, 2570	1.5 (s, 1H, SH), 4.95 (s, 1H, SCH), 5.1 (s, 1H, OH), 6.62 (d, 2H, Ar), 7.21 (d, 2H, Ar), 7.9 (s, 1H, NH)	258-259
5a		90% yellow	760, 1640, 3315, 1252, 2562,	2.1 (s, 3H, S-CH ₃), 3.73 (s, 3H, O-CH ₃), 4.95 (s, 1H, SCH), 6.65 (d, 2H, Ar), 6.95 (d, 2H, Ar), 7.8 (s, 1H, NH)	244-245
5b		82% yellow	764, 1633, 1312, 2650, 1250,	1.30 (t, 3H, CH ₃ -CH ₂ -S), 1.61 (t, 3H, CH ₃ -CH ₂ -O), 3.1 (q, 2H, CH ₂ -CH ₂ -S), 4.1 (q, 2H, CH ₂ -CH ₂ -O), 5.0 (s, 1H, SCH), 6.64 (d, 2H, Ar), 7.1 (d, 2H, Ar), 7.9 (s, 1H, NH)	147-148
5c		71% Yellow	755, 1650, 3320, 1253, 2556,	0.97 (t, 6H, CH ₃), 1.74 (m, 2H, CH ₂ -CH ₂ -O), 2.0 (m, 2H, CH ₂ -CH ₂ -S), 3.93 (t, 2H, CH ₂ -O), 4.95 (s, 1H, SCH), 6.65 (d, 2H, Ar), 6.95 (d, 2H, Ar), 7.99 (s, 1H, NH)	140-141
5d		72.5% Yellow	761, 1625, 3310, 1260, 2630,	2.6 (d, 2H, Ph-CH ₂ -CS), 4.93 (s, 1H, SCH), 6.94 (m, 4H, α - β system for benzene ring attack to the heterocyclic ring), 7.7 (s, 1H, NH), 7.14 (m, 10H, α - β system for two phenyl rings)	206-207

Table 1 Structure, IR, ¹H-NMR, yield and melting point data For all derivatives




Fig -1- The IR spectra of compound (3)




Fig -2- The IR spectra of compound (4)




Fig -3- the ^1H NMR spectra of compound (5c)




Fig -4- the ^1H NMR spectra of compound (4)

References

- 1- Invidiata F.P., Grimaudo S., Giammanco P., Giammanco L., *Farmaco*, 1991, **46**, 1489-1495.
- 2- Iqbal R., Rama N.H., Ahmad N., Zamanikh., Ebrahim S., Iqbal N., *Indian J.Chem.*, 1998, **37B**, 506-509.
- 3- Iqbal R., Rama N.H., Yunus u., saeed A., Zamani KH., *J.Chem.Soc. Pakistan*, 1997, **19**, 145-149.
- 4- Iqbal R., Zamani kh., Rama N.H., *Turk.J.Chem.*, 1996, **20**, 295-301.
- 5- Pendeya S.N., Sriram D., Nath G., de Clercq E., *Arzneim-Forsch- Drug Res*. 2000, **50**, 55-590
- 6- Sawhney S.N., Sharma P.K., *Bioorg. Med. Chem. Lett.*, 1993, **3**, 1551-1554.
- 7- Sorba G., Di Stilo A., Gasco A.M., Gili M., Gasco A., Orsetti M., *Farmaco*, 1992, **47**, 1445-1455.
- 8- Srivastava K., Panty S.N., *Bioorg. Med. Chem. Lett.*, 1993, **3**, 547-552.
- 9- Todoulo O.G., Papaclaki- Valiraki., Filippators E. C., I keda S., De Clercq E., *Eur.j.Med. Chem.*, 1994, **29**, 127.
- 10- Omar, A., Mohsen, M.e., Aboul, W., Omainma M., *J. Heterocycl. Chem.* 1986, **23**, 1339.